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the CC BY-NC-ND license (http://creaAbstract Objective: To investigate potential associations of preoperative total testosterone
(TT) with tumor volume (TV) and grade of prostate cancer (PCa).
Methods: Patients who were under medications impacting on the hypothalamic-pituitary-
adrenal-testis-prostate axis were excluded. TT was measured preoperatively at least 1 month
after biopsies and TV was calculated on the removed prostate specimen. Other continuous var-
iables included total prostate specific antigen (PSA), percentage of positive cores (Pþ) and
weight (W) of the removed prostate. Patients were categorized according to the pathologic
Gleason score (pGS) in 3 groups (pGS 6, 7 and > 7). Invasion of the seminal vesicles was coded
as seminal vesicle invasion (SVI).
Results: The median levels of TT were significantly and increasingly higher from pGS 6com (A.B. Porcaro).
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Prostate cancer volume and preoperative testosterone plasma levels 27(14.7 nmol/L) to pGS 7 (15.0 nmol/L) and pGS > 7 (18.8 nmol/L). The median values of TV were
also detected significantly and increasingly higher from pGS 6 (5.6 mL) to pGS 7 (8.1 mL) and
pGS > 7 (14.8 mL). The median preoperative levels of PSA were also increasing from pGS 6 (5.9
mg/L) to pGS 7 (6.2 mg/L) and pGS > 7 (7.7 mg/L). There was a significant and positive corre-
lation of TV to PSA, TT and Pþ. Multiple linear regression analysis showed that TV was signif-
icantly and independently predicted by TT, PSA and Pþ. High grade PCa (pGS > 7)
independently associated with TV, TT, Pþ and SVI. The median density values of TT relative
to TV (quotient TT/TV) significantly decreased from pGS 6 (2.6 nmol/L/mL) to pGS 7
(1.9 nmol/L/mL) and pGS > 7 (1.4 nmol/L/mL). The median density values of PSA relative
to TV (quotient PSA/TV) also significantly decreased from pGS (1.1 mg/L/mL) to pGS 7
(0.7 mg/L/mL) and pGS > 7 (0.6 mg/L/mL).
Conclusion: The investigation shows that TT relates to volume and grade of PCa; moreover, the
density of TT relative to TV inversely associates with rate of increase of cancer that depends
on the grade of the tumour.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Biology of the prostate depends on the endocrine system
which includes the hypothalamus, the pituitary gland, the
adrenals and testes in which Leydig’s interstitial cells are
responsible for the production of 95% of all circulating
androgen in the form of testosterone. Androgens, estrogens
and pituitary hormones regulate prostate physiology.
Actually, prostate cancer (PCa) is the most studied
endocrine tumour which needs further clinical research in
order to explore etiology and physiopathology factors
relating to its natural history. The disease depends on the
androgens [1] and increases the levels of prostate-specific
antigen (PSA) [2,3]. Since the pioneering work of Higgins
and Hodges [1], androgens have been universally consid-
ered pivotal in the regulation of normal function and ma-
lignant growth of the prostate. Moreover, pretreatment
total testosterone (TT) serum levels have been detected
abnormal in the PCa population [4e7]. It has also been
hypothesized that PCa might produce a substance that al-
ters the normal function of the pituitaryetesticulareprostate
axis which responds by abnormal luteinizing hormone (LH)
and follicle-stimulating hormone (FSH) serum levels [4e11].
It has also been suggested that the impact of the disease on
the hypothalamicepituitaryetestiseprostate axis may be
more profound in high-grade tumours [11]; however, the
hypothesis has not been confirmed [12]. The association of
pretreatment TT levels with pathological Gleason score
(pGS), which represents the most effective factor for pre-
dicting the natural history of the disease (biochemical
recurrence, development of metastases and PCa specific
mortality) [13e16], is still a controversial and unsettled
subject area [4e7,10e12,17e29] which requires further
research [30].
In PCa patients, the volume of the tumour (TV) has been
related to metastasis, seminal vesicle invasion and loss of
histological differentiation [31]; moreover, high grade tu-
mours (Gleason pattern 4 or 5) showed the highest rate to
metastasize [31]. As a consequence, the association of high
grade PCa with TV might express the highest potential ofaggressive disease. Actually, the potential association of
preoperative TT with both TV and high grade PCa remains
an unexplored area of clinical research which is subject of
the present investigation.
2. Materials and methods
2.1. Patients
The present analysis was part of a study aimed at evalu-
ating a potential link between PCa and the hypothal-
amicepituitaryetestiseprostate axis. The data of 220
operated patients were retrospectively reviewed. Standard
retro-pubic radical prostatectomy (RRP) was the surgical
procedure performed with or without limited local lymph
node dissection (LND). All patients had not previously
received 5a-reductase inhibitors, LH-releasing hormone
analogues or testosterone replacement treatment. The 14-
core transrectal ultrasound scan (TRUS) guided prostate
biopsy technique was routinely used and additional cores
were taken when a lesion on either TRUS or digital rectal
examination was evident. The biopsy Gleason score (bGS)
of positive cores was assessed and percentage of positive
cores (Pþ) was computed. After informed signed consent,
pretreatment simultaneous serum samples of TT and PSA
were obtained from a cubital vein, at least 1 month after
TRUS biopsy, between 8:00e8:30 a.m. The samples were
analyzed at our laboratory. TT (normal range, 9e29 nmol/L)
and PSA (normal range, 2e4 mg/L) were measured by
immunochemiluminescent test performed by ADVIA
Centaur XP Immunoassay System (Siemens Company,
Munich, Germany). The study obtained Institutional Review
Board approval.
2.2. Data collection
The prostatectomy specimens were fixed in toto overnight
(10% neutral buffered formhaldeyde), coated with India ink
and then weighted (W). Tissue sections of 4 mm were
28 A.B. Porcaro et al.prepared in standard fashion and stained with hematoxylin
and eosin. Patients were classified according to primary
tumour stage, lymph node and metastatic status, using the
TNM categories recommended by the 1997 International
Union Against Cancer TNM classification system [32]. Sem-
inal vesicle invasion (SVI) was defined as tumour involve-
ment of the muscolar wall (pT3b). Bladder neck invasion
was staged as pT3a. Surgical margins (R) were stated as
free (R0) or involved by cancer (R1). Tumours were graded
according to the Gleason grading system and the Gleason
score was computed after summing up the two patterns,
prevalent and secondary, structuring the tumour. High
grade PCa was defined as pGS> 7. The percentage of can-
cer volume (Vþ) was not directly measured but calculated
by the experienced and dedicated pathologists. Overall Vþ
was related to the volume of the removed prostate (PV, mL)
which was computed as the quotient W (prostate tissue
specific weight Z 1.05). TV (mL) was calculated by multi-
plying PV and Vþ. It was also assessed the tumour rate
which was defined as the median rate of increase of the
mass (volume) of the tumour related to each unit increase
of the pGS.Table 1 Variables in the PCa population and their association w
Variable Population pGS
(n Z 220) 6 (n Z 88)
Age (year)a 67 (45e78) 66.5 (51e75)
PSA (mg/L)a 6.2 (1.2e44.2) 5.9 (1.3e38.6)
TT (nmol/L)a 15.5 (5.5e40.7) 14.7 (6.9e33.6)
Pþ (prop)a 0.31 (0.05e1.00) 0.21 (0.06e1.00)
W (g)a 50.5 (20.0e225.0) 56.2 (25.1e225.0)
TV (mL)a 7.4 (0.6e47.6) 5.6 (0.6e47.6)
cTb
1c 117 (53.2) 59 (26.8)
2a/b 61 (27.7) 17 (7.7)
2c 38 (17.3) 12 (5.5)
3 4 (1.8) 0 (0.0)
bGSb
6 130 (59.1) 79 (35.9)
7 79 (35.9) 9 (4.1)
>7 11 (5.0) 0 (0.0)
pTb
2a/b 23 (10.5) 18 (8.2)
2c 102 (46.8) 51 (23.2)
3a 74 (33.6) 18 (8.2)
3b 21 (9.5) 1 (4.8)
pRb
0 132 (60.0) 64 (29.1)
1 88 (40.0) 24 (10.9)
pNb
0 38 (17.3) 11 (5.0)
1 8 (3.6) 1 (0.5)
x 174 (79.1) 76 (34.5)
TV, tumour volume; TT, total testosterone; PCa, prostate cancer; pG
biopsy Gleason score; Pþ, positive cores; W, weight. According to Am
ological lymphnode status; pR, pathological surgical margin status (p
a Presented as median (range).
b Presented as n (%).2.3. Statistical methods
Data on continuous variables are presented as medians with
their respective ranges, and differences between groups
analysed with the ManneWhittney U test and Kruskal Wallis
test. Data on categorical variables are presented as pro-
portions, and differences between groups analysed with
Pearson’s chi-squared or Fishers’ exact test as appropriate.
The association of TV was assessed by univariate and
multivariate linear regression analysis which was preceded
by evaluation of co-linearity of the covariates which
included age, PSA, TT, Pþ and W. The associations of high
grade PCa was investigated by the logistic regression model
in which all variables were entered as continuous variables
expect for SVI which was dichotomous (1 Z positive,
0 Z negative); moreover, the variables were grouped as
clinical (PSA, TT, Pþ) and pathologic (TV, SVI). All tests are
two-sided with p < 0.05 considered to indicate statistical
significance.ith pGS groups.
7 (n Z 109) >7 (n Z 23) p-Value
67 (45e78) 68 (54e75) 0.19
6.2 (1.2e44.2) 7.7 (3.4e36.7) 0.056
15 (5.5e40.7) 18.8 (9.2e31.3) 0.015
0.40 (0.05e1.00) 0.50 (0.07e1.00) <0.0001
48.0 (20.0e159.0) 45.0 (28.0e93.0) 0.001
8.1 (1.1e35.0) 14.8 (2.9e33.4) <0.0001
<0.0001
51 (23.2) 7 (3.2)
38 (17.3) 6 (2.7)
19 (88.6) 7 (3.2)
1 (0.5) 3 (1.4)
<0.0001
48 (21.8) 3 (2.3)
57 (25.9) 13 (5.9)
4 (1.8) 7 (3.2)
<0.0001
5 (2.3) 0 (0.0)
50 (22.7) 1 (0.5)
44 (20.0) 12 (5.5)
10 (4.5) 10 (4.5)
<0.0001
62 (28.2) 6 (2.7)
47 (21.4) 17 (7.7)
<0.0001
20 (9.1) 7 (3.2)
2 (0.9) 5 (2.3)
87 (39.5) 11 (5.0)
S, pathologic Gleason score; PSA, prostate specific antigen; bGS,
erican Joint Committee on Cancer: cT, clinical stage; pN, path-
R Z 1, involved; pR Z 0, not involved); pT, pathological stage.
Table 2 Correlations of TV in the operated prostate
cancer population (n Z 220).
Variables Stat W Age PSA TT Pþ
TV r 0.035 0.10 0.345 0.158 0.388
p-Value 0.60 0.11 <0.0001 0.019 <0.0001
W r 0.168 0.056 0.003 0.302
p-Value 0.013 0.412 0.969 0.0001
Age r 0.094 0.044 0.036
p-Value 0.16 0.519 0.598




r, Pearson’s correlation coefficient.
TV, tumour volume; TT, total testosterone; PSA, prostate
specific antigen; Pþ, positive cores; W, weight.
Table 3 Covariates associating with TV in the prostate
cancer population (n Z 220).
Variable b SE 95% CI p-Value
Univariate linear regression
PSA 0.371 0.068 0.236e0.506 <0.0001
TT 0.19 0.08 0.033e0.360 0.019
Pþ 13,307 2.13 9.09e17.52 <0.0001
Multivariate linear regression
PSA 0.28 0.06 0.16e0.41 0.0001
TT 0.18 0.07 0.04e0.33 0.012
Pþ 11.34 2.07 7.25e15.43 0.0001
Multivariate clinical model
PSA 0.29 0.06 0.16e0.41 <0.0001
TT 0.19 0.07 0.05e0.34 0.007
Pþ 9.38 2.22 5.00e13.77 <0.0001
bGS 7 2.21 0.97 0.30e4.12 <0.0001
Intercept (0.238) 1.5 (3.194)e 2.71 0.87
95% CI, 95% confidential interval; TV, tumour volume; TT, total
testosterone; PSA, prostate specific antigen; bGS, biopsy
Gleason score; Pþ, positive cores; W, weight.
Prostate cancer volume and preoperative testosterone plasma levels 293. Results
Part of the clinical and pathologic characteristics of the
cohort of cases has already been reported elsewhere
[33,34]. Table 1 reports the clinical and pathological factors
of the cohort of patients who have been stratified according
to the pGS. The clinical characteristics of the patient
population are presented in Table 1. At the time of pre-
sentation, 190 patients (98.2%) had clinically organ-
confined disease, the median (range) levels of PSA and TT
were 6.2 (1.2e44.2) mg/L and 15.5 (5.5e40.7) nmol/L,
respectively. The distribution of pGS was 6 in 88 (40.0%), 7
in 109 (49.5%) and >7 in 23 (10.5%) cases, and the median
(range) of TV was 7.4 (0.6e47.6) mL.
The clinical and pathological characteristics of the
different pGS groups are also reported in Table 1 which
shows increasing median values of PSA (p Z 0.056), TT
(p Z 0.015), TV (p < 0.0001), Pþ (p < 0.0001) and
decreasing values of W (p Z 0.001). The proportions of cT,
bGS, pT, R and pN were also significantly different
(p < 0.0001).
As shown in Table 2, TV correlated with PSA (r Z 0.345,
p < 0.0001), TT (rZ 0.158, pZ 0.019) and Pþ (rZ 0.388,
p < 0.0001) which also correlated with PSA (r Z 0.215,
pZ 0.001) and W (rZ 0.302, pZ 0.0001). As reported in
Table 3, multivariate linear regression analysis showed that
PSA (pZ 0.0001), TT (pZ 0.012) and Pþ (pZ 0.0001) were
independent predictors of TV. The functional relations of TV
to TT and PSA are depicted in Fig. 1(A) and (B), respectively.
Table 4 describes logistic regression results which
showed that high grade cancer (pGS>7) independently
associated with preoperative variables including PSA
(pZ 0.023), TT (pZ 0.010) and Pþ (pZ 0.016) as well as
with postoperative covariates including pT3b (p < 0.0001)
and TV (p Z 0.025).
To explore the association of both PSA and TT with
tumour grade, we estimated the amount of PSA and TT
produced per unit volume of tumour tissue, the quotients
PSA/TV and TT/TV, by Gleason score in the 220 RRP spec-
imens. As shown in Table 5, TV was closely related to pGS
with median TV almost increasing three times from pGS 6 to
pGS>7 (p < 0.0001). Although the increases of the median
levels of TT, as shown in Fig. 1 (C), were significant
(p Z 0.015), more than PSA (p Z 0.056), the rate of rise
was less than TV, such that with increasing tumour rate, the
amount of TT and PSA relative to unit volume of tumour
dropped significantly (p < 0.0001).Figure 1 The associations of TV with TT (A), TV with PSA (B), and
groups. TV, tumour volume; TT, total testosterone; pGS, pathologi4. Discussion
Prostate cancer volume has been related to grade and stage
[35] as well as to PSA [2], PSA density (PSAD, quotient PSA/
prostate volume) and to the quotient PSA/TV [35].TV as a function of the density (TT/TV) (C) are stratified by pGS
c Gleason score; PSA, prostate specific antigen.
Table 4 Covariates associating with pGS>7.
Covariate b SE OR 95% CI for OR p-Value
Univariate logistic regression
Preoperative PSA 0.071 0.023 1.074 1.027e1.160 0.002
Preoperative TT 0.085 0.032 1.088 1.021e1.160 0.009
Preoperative Pþ 2.692 0.637 14.763 2.397e90.921 0.004
TV 0.095 0.024 1.099 1.049e1.152 <0.0001
pT3b 2.565 0.523 13.007 4.669e36.132 <0.0001
Multivariate logistic regression
Preoperative PSA 0.072 0.027 1.057 1.020e1.133 0.007
Preoperative TT 0.118 0.039 1.125 1.041e1.215 0.003
Preoperative Pþ 0.621 1.199 1.860 0.178e19.488 0.605
Preoperative bGS7 2.866 0.769 17.574 3.895e79.285 <0.0001
TV 0.059 0.026 1.061 1.007e1.117 0.025
pT3b 2.036 0.580 7.569 2.457e23.879 <0.0001
95% CI, 95% confidential interval; bGS, biopsy Gleason score; PSA, prostate specific antigen; TT, total testosterone; TV, tumour volume.
30 A.B. Porcaro et al.However, the relation of TV to TT serum levels has not yet
been investigated. The present study shows functional re-
lationships of PCa. Interestingly, TV was independently
predicted by the preoperative covariates including PSA, TT
and Pþ. Although significantly higher median values of both
TT and PSA were detected in the pGS groups, the density of
TT and PSA relative to TV (quotients TT/TV and PSA/TV)
were inversely related to pGS. Indeed, in the pGS groups,
the rate of rise of both PSA and TT was less than TV, such
that with increasing tumour rate, the amount of TT and PSA
relative to unit volume of tumour dropped significantly (see
Fig. 1 (C)). As a consequence, high grade tumours, although
associating with increased median levels of TT and PSA,
express low TT and PSA densities relative to mass of the
tumour. Probably, the three important steps in the natural
history of PCa are: (i) the development of microfoci of
incidental cancer, (ii) the progression from occult to sig-
nificant localized disease, and (iii) metastasis to lymph
nodes, bones or other organs. The progression of PCa from
occult to clinically significant disease might be related to
multiple genetic hits which are necessary for trans-
formation into clinically significant cancer. The molecular
biology that underlies the maintenance of androgen receptorTable 5 Analysis of PSA and TT production per unit volume of
Variable Stat pGS
6 (n Z 88)
TV (mL) median (range) 5.6 (0.6e47.6)
mean  SD 6.9  6.3
PSA (mg/L) median (range) 5.9 (1.3e38.6)
mean  SD 7.1  5.1
TT (nmol/L) median (range) 14.7 (6.9e33.6)
mean  SD 15.8  5.0
PSA/TV (mg/L/mL) median (range) 1.1 (0.1e13.1)
mean  SD 1.6  2.0
TT/TV (nmol/L/mL) median (range) 2.6 (0.6e30.9)
mean  SD 3.9  4.2
TV, tumour volume; TT, total testosterone; pGS, pathologic Gleason(AR) activity in the early stages of PCa progression might be
related to endocrine androgen dependence (state 1) and
intracrine androgen dependence (state 2); indeed, in both
states the drivers of AR pathway are androgens which are
produced by the testes in state 1 and by PCa cells either
from adrenal precursors or trough de novo metabolism in
state 2 [36]. As a theory, the high TT/TV density of pGS 6
might be related to state 1 (endocrine androgen depen-
dence) and the low density of pGS 7 and >7 to state 2
(intracrine androgen dependence). Moreover, PSA is the
ultimate androgen responsive gene and its incremental
decline production in less differentiated tumours (low
PSA/TV density) might also be related to intracrine androgen
dependence. In our opinion, the present study gives evi-
dence of how TV relates to pGS groups.
Tumour grade is the best predictor of PCa natural history
after RP [13e16]. The topic dealing with the association of
preoperative TT levels and tumour grade is controversial.
Indeed, studies investigating on the potential relation of TT
to tumour grade have shown that the former might or might
not be associated with the latter; moreover, when the
relation was significant, both lower and higher mean serum
levels of TT related to high grade tumours as well [30]. Ourtumour by Gleason grade.
7 (n Z 109) >7 (n Z 23) p-Value
8.1 (1.4e35.0) 14.8 (2.9e33.4) <0.0001
10.2  6.8 16.2  9.4
6.2 (1.2e44.2) 7.7 (3.4e36.7) 0.05
7.9  7.1 7.7  10.0
15.0 (5.5e40.7) 18.8 (9.2e31.3) 0.015
16.2  6.6 18.8  6.1
0.7 (0.1e24.0) 0.6 (0.1e6.3) <0.0001
1.1  2.4 1.1  2.3
1.9 (0.3e9.1) 1.4 (0.3e9.1) <0.0001
2.3  1.6 1.9  2.0
score; PSA, prostate specific antigen.
Prostate cancer volume and preoperative testosterone plasma levels 31study showed that higher median levels of TT were detec-
ted in high grade PCa (pGS >7), but it is difficult to compare
with other studies showing the opposite. Indeed, the results
of studies stating that significantly lower levels of TT are
detected in high grade tumours have to be evaluated by the
criteria employed to group the patient population. For
example, Zhang et al. [27] demonstrated that significantly
lower levels of TT were detected in high grade PCa tu-
mours; however if we consider the methodological criteria
which were employed, we see that tumour grades were
assessed according to the limitations of the bGS, also, high
grade tumours included 8e9 groups and “moderate can-
cers” included bGS 5e7. In our opinion, before trying to
find out significant associations of lower serum levels with
high grade tumours, an evident and independent associa-
tion between TT serum levels and the GS groups has to be
assessed. The present investigation shows the close asso-
ciation of TT with both volume and grade of the tumour.
Although low and high levels of TT may be assessed in the
pGS groups, the levels of TT which may be low or high,
relate differently to TV measurements in the pGS groups.
Indeed, tumours having same volume measurements
associate with different serum levels of TT in the pGS
groups. For example, PCa related to TV of 10 mL associate
with lower TT levels in high-intermediate cancers
compared to pGS 6 tumours. As a theory, TT is closely
related to the tumour phenotype, while PSA is the product
of the ultimate responsive gene depending on TTwhich is a
stimulatory growth factor for the cancer cell population.
Tumour grading related to both TT and TV might identify
different degrees of hormone dependence in the pGS
groups; indeed, low-intermediate grade tumours probably
contain a higher proportion of androgen dependent cancer
cells in their population and high grade groups might
include a cancer population which is predominantly
androgen independent. The findings of the present study
might explain why higher levels of calculated FT, which
depends on TT, were associated with an increased risk of
aggressive PCa among older men [37]. The study also
stresses the importance of preoperative serum TT along the
hypothalamicepituitaryetestiseprostate axis in which
hormonal and PSA dynamics will change after radical
prostatectomy [4e11].
There are several limitations to the present investiga-
tion. Firstly, although the data were collected prospec-
tively, it was analyzed retrospectively. In addition, the
volumes measured by TRUS were incomplete, and so PSAD
was not included in the analysis; however, results related to
PSAD could have been confirmatory of what has been
widely reported from the literature.
The third limit might be related to the methodology
employed to measure TV; however, the computation is sim-
ple and reproducible and the results are close to what has
been reported in the literature [31,32]. Themeasurement of
Vþ is standard in daily pathology practice and it was
computed by experienced pathologists; moreover, it was
related to tumour volume according to the methodology
described. The analysis confirmed that the computations
were reliable and significantly related to the preoperative
and pathologic variables. We did not directly measure TV by
sophisticated and complex methodologies which are also
difficult to reproduce in clinical practice because the maingoal of the studywas assess this parameter indirectly in order
to be reproducible in each urologic unit that has dedicated
pathologists and there is each other feed-back in
approaching prostate cancer. However, TV and pT both
independently associated with pGS which is the strongest
predictor PCa natural history. Fourth, although there were
only 23with pGS>7which is 10% of the cohort, the group that
was classified by pGS>7 was really the high grade group of
the cohort according to the new classification system of PCa
that has been proposed by the International Society of Uro-
logic Pathology (ISUP) Consensus Conference [38].
Although our multivariate models might be unstable
because of wide confidence intervals, confirmatory studies
of our results are required. However, multiple analyses
have been computed in order to show that the pathologic
variables including TV and pT as well as the clinical factors
including TT, PSA and Pþ independently associated with
pGS which is the strongest recognized predictor of the
natural history of prostate cancer. Finally, comparing and
confirmatory studies are missing. However, in our opinion,
the topic has been approached in an advanced way and the
results are interesting for evaluating and managing clinical
PCa.
In summary, we have determined that preoperative TT
relates to volume and grade of PCa; moreover, the quotient
TT/TV (density) inversely associates with the rate of in-
crease of the tumour that also associates with PCa grade. TT
might be a potential marker for assessing preoperatively the
volume and grade of PCa. These findings might have obvious
implications in clinical practice; however, confirmatory
studies are required in this controversial research area.Conflicts of interest
The authors declare no conflict of interest.References
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